MX2021011746A - Formulacion de combinacion triple de dosis baja. - Google Patents

Formulacion de combinacion triple de dosis baja.

Info

Publication number
MX2021011746A
MX2021011746A MX2021011746A MX2021011746A MX2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A
Authority
MX
Mexico
Prior art keywords
inhibitor
low
dose
combination formulation
triple combination
Prior art date
Application number
MX2021011746A
Other languages
English (en)
Inventor
Anthony Rodgers
Stephen Macmahon
Original Assignee
The George Inst For Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The George Inst For Global Health filed Critical The George Inst For Global Health
Publication of MX2021011746A publication Critical patent/MX2021011746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan en la presente composiciones farmacéuticas que son útiles para el tratamiento de diabetes y afecciones, enfermedades y trastornos asociados.
MX2021011746A 2019-03-25 2020-03-25 Formulacion de combinacion triple de dosis baja. MX2021011746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (1)

Publication Number Publication Date
MX2021011746A true MX2021011746A (es) 2021-10-22

Family

ID=72606637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011746A MX2021011746A (es) 2019-03-25 2020-03-25 Formulacion de combinacion triple de dosis baja.

Country Status (11)

Country Link
US (5) US11033544B2 (es)
EP (1) EP3946344A4 (es)
JP (1) JP2022529208A (es)
KR (1) KR20220004027A (es)
CN (1) CN113924096A (es)
AU (1) AU2020247542A1 (es)
BR (1) BR112021018994A2 (es)
CA (1) CA3134800A1 (es)
MX (1) MX2021011746A (es)
TW (1) TW202102209A (es)
WO (1) WO2020194052A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
MY160123A (en) * 2009-02-13 2017-02-28 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US20170135981A1 (en) 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Also Published As

Publication number Publication date
US20220226316A1 (en) 2022-07-21
US20210260056A1 (en) 2021-08-26
US11033544B2 (en) 2021-06-15
AU2020247542A1 (en) 2021-11-11
CA3134800A1 (en) 2020-10-01
BR112021018994A2 (pt) 2022-02-08
EP3946344A1 (en) 2022-02-09
KR20220004027A (ko) 2022-01-11
US20220226315A1 (en) 2022-07-21
EP3946344A4 (en) 2022-12-28
JP2022529208A (ja) 2022-06-20
TW202102209A (zh) 2021-01-16
US20200306246A1 (en) 2020-10-01
US20220226317A1 (en) 2022-07-21
CN113924096A (zh) 2022-01-11
WO2020194052A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
WO2008064107A3 (en) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
WO2004043377A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
MX2021011745A (es) Formulacion de combinacion triple baja en dosis.
MX2019012884A (es) Terapia de combinacion.
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021011746A (es) Formulacion de combinacion triple de dosis baja.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
MX2022003096A (es) Tratamiento de la diabetes mellitus tipo 2.
MX2022015333A (es) Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2.
WO2023230348A3 (en) Dosage regimens for treatment of dengue infection
MX2022001023A (es) Compuestos de aminotiolester y usos de los mismos.
MX2022001200A (es) Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.
CR20220453A (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물